Feds Rush Psychedelic Drug Approvals While Colorado Risks Abandoning Voter-Backed Natural Medicine Program

Two recent moves have dramatically changed how psychedelic medicines will reach Americans. On April 18, President Donald Trump signed an executive order accelerating federal review of psychedelic drugs targeting serious mental illnesses like treatment-resistant depression and PTSD. Within days, the FDA awarded priority review vouchers to three companies developing psilocybin and MDMA-related therapies, potentially shrinking the approval process from a typical 10-to-12 months to as little as one or two months.

Just two days later, Colorado Governor Jared Polis quietly signed Senate Bill 26-31, which automatically legalizes pharmaceutical psilocybin in the state the moment the DEA reschedules any FDA-approved Schedule I psychedelic drug. This move signals Colorado’s readiness to embrace prescription-based psychedelic therapies as soon as federal green lights arrive.

But there is a catch that many overlook. Colorado’s law explicitly preserves the voter-approved Proposition 122 natural medicine program, which supports facilitator-led healing centers offering community-based psychedelic experiences. This dual-path approach is rare nationwide, where most states pick either a medicalized or a community-centered model—never both.

This matters because these two paths serve fundamentally different needs. Medicalized psilocybin therapy, often covered by insurance, targets patients with treatment-resistant depression or PTSD under clinical supervision. Meanwhile, the natural medicine program supports people seeking healing through ceremony, community, and traditional practices. Both are legitimate, but they demand different frameworks, training, and cultural respect.

The danger now is that the rapid federal push for pharmaceutical psychedelics will eclipse Colorado’s natural medicine program. Some might assume community access is obsolete once prescription options arrive, risking underfunding and neglect of facilitator licensing, healing center regulation, and equitable access efforts. That would betray the voters who chose a broader vision with Prop 122.

Advocates urge Colorado legislators and regulators to double down on implementing Prop 122 with integrity. This means funding and staffing the natural medicine infrastructure, defending it against the overwhelming federal model’s gravitational pull, and ensuring the community pathway remains vibrant and accessible.

Practitioners preparing to prescribe psychedelics also face a critical moment. The FDA’s accelerated review timeline does not equate to readiness to safely administer these powerful medicines. Proper training, understanding of non-ordinary states of consciousness, and integration support take time and cannot be rushed.

Finally, Coloradans themselves must engage in upcoming rulemaking processes that will determine how the natural medicine program unfolds locally. Public input is essential to preserving the wider path voters demanded.

As psychedelic medicines arrive faster than expected, Colorado stands at a crossroads. It can either let the federal medicalized model consume all access or hold firm to the dual approach that honors both clinical innovation and community healing traditions. The choice is urgent and consequential—for Colorado and for other states watching closely.

We will be watching. And we will keep calling out any effort to narrow access and betray the voters’ intent. The future of psychedelic healing depends on holding both paths with care and integrity.